Maxigen BiotechTPE:1783 -1.55%87 Beneish M-Score is -2.48 as of Jun. 26, 2026. GuruFocus rates TPE:1783 with a GF Score™ of 87/100 and a GF Value™ of NT$60.99 (Significantly Undervalued). Among 766 Medical Devices & Instruments companies, Maxigen Biotech ranks worse than 59.66% on this metric.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Good Sign:
Beneish M-Score -2.48 no higher than -1.78, which implies that the company is unlikely to be a manipulator.
The historical rank and industry rank for Maxigen Biotech's Beneish M-Score or its related term are showing as below:
TPE:1783'
s Beneish M-Score Range Over the Past 10 Years
Min: -3.89 Med: -2.5 Max: 5.87
Current: -2.48
During the past 13 years, the highest Beneish M-Score of Maxigen Biotech was 5.87. The lowest was -3.89. And the median was -2.50.
Maxigen Biotech Beneish M-Score Related Terms
Maxigen Biotech Beneish M-Score Historical Data
* Premium members only.
The historical data trend for Maxigen Biotech's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1783 vs ISRG, BDX, MDLN: Beneish M-Score Comparison
For the Medical Instruments & Supplies subindustry, Maxigen Biotech's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maxigen Biotech Beneish M-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Maxigen Biotech's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Maxigen Biotech for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 1.067
+
0.528 * 1.0223
+
0.404 * 0.8542
+
0.892 * 1.1923
+
0.115 * 0.8732
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 0.8715
+
4.679 * -0.013157
-
0.327 * 1.4175
=
-2.48
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(27.024 / (27.024 + 430.363))
/
(32.136 / (32.136 + 442.834))
=
0.059083
/
0.067659
=
0.8732
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(265.312 - 0
-
290.22)
/
1893.142
=
-0.013157
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Maxigen Biotech has a M-score of -2.48 suggests that the company is unlikely to be a manipulator.
Maxigen Biotech (TPE:1783) has a Beneish M-Score of -2.48 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Maxigen Biotech and its competitors. According to the industry distribution chart, Maxigen Biotech ranks #457 out of 766 companies in the Medical Devices & Instruments industry, placing it in the top 59.7%.
Is Maxigen Biotech's Beneish M-Score too high?
Maxigen Biotech's current Beneish M-Score is -2.48. Based on the distribution chart, Maxigen Biotech ranks #457 out of 766 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Maxigen Biotech has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maxigen Biotech's Beneish M-Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Maxigen Biotech ranks #457 out of 766 companies for Beneish M-Score. This places Maxigen Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Maxigen Biotech and its competitors. Maxigen Biotech's current Beneish M-Score is -2.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maxigen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$60.99, compared to a current price of NT$38.10 — trading 37.5% below its estimated fair value. The current Beneish M-Score is -2.48. Maxigen Biotech's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current Beneish M-Score is -2.48 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maxigen Biotech (TPE:1783) Overvalued in 2026?
Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued.
The current stock price of NT$38.10 is trading 37.5% below its estimated GF Value™ of NT$60.99.
GuruFocus considers Maxigen Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1783:
Beneish M-Score: -2.48
GF Value™: NT$60.99 vs. price of NT$38.10 (37.5% below fair value)
No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score
Get the complete analysis for TPE:1783
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1783 has been successfully added to your 
